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Helios, a novel dimerization partner of Ikaros expressed in the
earliest hematopoietic progenitors
Clair M. Kelley*, Tohru Ikeda†, Joseph Koipally*, Nicole Avitahl*, Li Wu‡, Katia
Georgopoulos* and Bruce A. Morgan†
Background: Normal hematopoietic development depends on the activity of
the Ikaros transcription factor, which contains distinct zinc-finger domains that
mediate DNA binding and protein dimerization. Mice homozygous for a
transgene encoding a dominant-negative version of Ikaros that lacks the DNA-
binding domain but not the dimerization domain have a more severe phenotype
than Ikaros null mice. This observation suggests the presence of factor(s) that
can dimerize with Ikaros and partially complement its function. One previously
identified factor, Aiolos, probably serves this role in the lymphoid system; a
related factor involved in hematopoietic progenitors remains unknown, however.
Results: Here, we describe the cloning of an Ikaros-related gene, Helios.
Analysis of the primary sequences of Helios, Ikaros and Aiolos revealed that the
DNA-binding, transcriptional activation and dimerization domains are
functionally conserved. Helios activated transcription from Ikaros DNA-binding
sites and could dimerize with itself, Ikaros or Aiolos. Expression of Helios was
detected in the earliest hematopoietic sites of the embryo, in hematopoietic
stem cells in the adult and was subsequently restricted to a subset of cells in
the T cell lineage. Helios co-localized with Ikaros and Aiolos proteins in
macromolecular nuclear structures and formed stable complexes in vivo with
the dominant-negative version of Ikaros.
Conclusions: Distinct but overlapping expression patterns of members of the
Ikaros gene family during hematopoiesis might result in the formation of
different multimeric complexes that have specific roles in lineage progression.
The preferential expression of Helios in the earliest stages of hematopoiesis
suggests that this gene functions predominantly in early progenitors.
Background
Hematopoiesis involves the generation of pluripotent
hematopoietic stem cells (HSCs) and their subsequent
restriction and differentiation along one of at least seven
distinct lineages. Hematopoiesis begins in two sites of the
early embryo: the blood islands of the yolk sac and the
splanchnopleural mesoderm that becomes the
aorta–gonad–mesonephros (AGM) region [1,2]. By late
gestation, the fetal liver becomes the major site of
hematopoiesis. After birth, HSCs are found in the bone
marrow where they undergo self-renewal and replenish
the various lineages throughout adult life. At this site, the
fate of the HSC is controlled by environmental cues that
ultimately signal to transcription factors that are pivotal for
lineage decisions [3,4]. 
Among the lineage-determining transcription factors, Ikaros
is required for the normal development and homeostasis of
the lymphoid system [5–9]. Ikaros mRNA is detected in the
earliest defined HSC progenitor and continues to be
expressed throughout the development of the lymphoid
lineages [5,10,11]. The Ikaros gene is alternatively spliced
and the resulting mRNA species produce at least six distinct
isoforms containing between one and four amino-terminal
Krüppel-type zinc fingers which dictate the sequence speci-
ficity and DNA-binding affinity of the isoforms [12,13]. All
of the Ikaros isoforms have two Krüppel-like zinc fingers at
their carboxyl termini which mediate protein dimerization
[14]. Formation of homodimers and heterodimers between
the DNA-binding Ikaros isoforms — Ik-1, Ik-2 and Ik-3 —
dramatically increases both their affinity for DNA and their
ability to activate transcription from their cognate DNA-
binding sites. An Ikaros heterodimer in which one of the
monomers lacks a DNA-binding domain cannot bind DNA,
however, and is therefore transcriptionally inert. 
The importance of Ikaros in the ontogeny and homeosta-
sis of the immune system has been demonstrated through
the analysis of two different targeted mutations in the
Ikaros gene [6,9]. Mice homozygous for a functionally null
mutation in the Ikaros gene, which results in the deletion
of the dimerization domain and destabilization of the
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protein, lack natural killer (NK) cells and B cells [9]. T
cells are absent in the fetus, but small numbers of T cell
progenitors appear in the thymus a few days after birth.
Further abnormalities in the differentiation of the postna-
tal T cell compartment include a skewing of thymocytes
toward the CD4+CD8– lineage and a hyperproliferative
response to T cell receptor stimulation [9]. 
A second Ikaros mutation, involving a deletion of the
amino-terminal DNA-binding domain of the Ikaros
protein, results in a more severe phenotype when
expressed in mice. This amino-terminal deletion mutant
acts in a dominant-negative fashion, as these proteins are
able to dimerize with wild-type isoforms and thereby
inhibit Ikaros activity. Mice homozygous for the Ikaros
dominant-negative (DN) mutation (Ikaros DN–/–) have a
complete block in B, T and NK cell differentiation in both
the fetus and the adult and have additional defects in the
HSC compartment ([6]; A. Nichogiannopoulou and K.G.,
unpublished observations). The more severe phenotypes
manifested by the Ikaros DN homozygotes (Ikaros DN–/–)
compared with the Ikaros null mice suggest that Ikaros
DN dimerizes and interferes with the activity of other
Ikaros-like factors in the hematopoietic system. 
This hypothesis led to the identification of the Ikaros-
related factor Aiolos, which is highly conserved in both the
DNA-binding and protein dimerization zinc-finger
domains [10]. Aiolos expression is restricted to the lym-
phoid lineages, and the protein can functionally interact
with Ikaros. Aiolos is critical during B cell differentiation
and its function in lymphocyte differentiation can be dis-
rupted by dimerization with Ikaros DN (J.H. Wang, N.A.,
C. Friedrich, T.I., A. Renold, K. Andrikopoulos, L. Liang,
B.A.M., K.G., unpublished observations). In addition to
the more severe lymphoid defects, however, the Ikaros
DN–/– mice also show defects in HSCs that are not
observed in Ikaros null mutants (A. Nichogiannopoulou
and K.G., unpublished observations). Whereas Ikaros is
expressed in the bone marrow population highly enriched
for HSC activity (c-Kit+Sca-1+lineage–; [15,16]), Aiolos is
not [10]. This suggests that the HSC abnormalities in the
Ikaros DN–/– mice result from the interference of Ikaros
DN with another factor(s). We therefore sought to identify
new Ikaros-related-interacting factors in the HSC popula-
tion. This led to the identification of Helios, a novel
member of the Ikaros gene family.
Results 
Identification of Helios, a novel Ikaros-related gene
Degenerate primers encoding conserved sequences in the
Ikaros amino-terminal (Ik-F) and carboxy-terminal zinc-
finger (Ik-R) domains [17] were used to amplify cDNAs
generated from the spleen of Aiolos null mutant mice
(Figure 1; J.H. Wang, et al., unpublished observations). A
PCR product of the expected size (980 bp) was cloned and
shown to have a unique DNA sequence that was homolo-
gous to the Ikaros gene. Full-length coding sequence was
obtained by rapid amplification of cDNA ends
(RACE)–PCR using nested specific internal primers. The
encoded protein, designated Helios, shows a high degree of
conservation to the Ikaros and Aiolos proteins (73% and
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Structure of the Helios gene product. Alignment of the predicted
amino-acid sequence of Helios with the sequences of Ikaros and
Aiolos. The four amino-terminal zinc fingers comprising the DNA-
binding domain are outlined in red, and the carboxy-terminal zinc
fingers that mediate protein dimerization are outlined in blue. The
conserved transcriptional activation domain is outlined in green.
Arrows indicate the conserved sequences to which the degenerate
oligos Ik-F (encoding GEKPFK) and Ik-R (encoding YTIHMG) were
designed [17] to clone the Helios gene. The sequence between the
purple arrows is present in the Hel-1 isoform, but absent from the Hel-
2 isoform. Amino acids outlined in black represent identical residues
and those outlined in gray represent conservative substitutions.
67% overall similarity, respectively). The three proteins are
almost identical throughout the amino-terminal zinc-finger
DNA-binding domain. The protein dimerization domain,
comprising the carboxy-terminal zinc fingers, is 86% identi-
cal between Helios and Ikaros and 75% identical between
Helios and Aiolos. In a third region that contains the tran-
scriptional activation domain, Helios has 68% similarity
with Ikaros and 70% identity to Aiolos. Two alternatively
spliced forms of Helios were identified. The full-length
isoform (Hel-1) is analogous to the Ikaros isoform Ik-1 in
that it encodes a protein that contains all four DNA-
binding zinc fingers. The second isoform (Hel-2) is similar
to Ik-2 in that its protein product is missing the first zinc
finger (Figure 1). The strong conservation of the amino-ter-
minal zinc-finger motifs encoded by Hel-1 and Hel-2 with
those of the Ikaros isoforms Ik-1 and Ik-2 predicts that they
will display similar DNA-binding properties [12].
Expression of Helios during embryogenesis
The expression of Helios during mouse embryogenesis was
compared with Ikaros by in situ hybridization to adjacent
sections. Helios is expressed in all hematopoietic centers of
the developing embryo. The blood islands of the yolk sac
constitute the first site of embryonic hematopoiesis. Helios
and Ikaros are expressed in this extraembryonic site at day
8 of gestation (Figure 2a–c). By day 11, however, Helios
expression has significantly decreased, whereas Ikaros
expression is maintained until embryonic day 13 in this
region (data not shown). Both Helios and Ikaros are
expressed in the liver at day 11, although Helios mRNA is
only present in a subset of cells in this tissue (Figure 2d–f).
Throughout hematopoietic development, Helios expression
in the liver is detected in a small number of scattered cells.
In contrast, Ikaros is expressed at high levels in most of the
cells present in this tissue during mid- to late-gestation
(Figure 2g,i). In the thymus, Helios is first detected at low
levels at embryonic day 13, whereas Ikaros expression is
readily detected in this site 2 days earlier (data not shown).
By day 16, Helios is expressed at high levels towards the
center of the thymus, a region where early progenitors
enter from the vasculature: in contrast, Ikaros is detected in
most thymocytes (Figure 2j–l). This pattern of Helios
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Developmental expression of Helios detected by in situ hybridization.
(a,d,g,j,m) Bright-field views of embryonic sections at various stages
with (b,e,h,k,n) dark-field views of Helios expression in the same
section. (c,f,i,l) Dark-field views of Ikaros expression in an adjacent
section for each stage. Helios is first detected in the yolk sac blood
islands (BI) of the day 8 embryo (b). Arrows point to the blood islands
in the dark-field views showing Helios and Ikaros expression. (e,f) At
day 11, both Helios and Ikaros are detected in the fetal liver (Li,
arrow). Helios is also expressed in the epithelial lining of the gut (G).
(h,i) At day 13, Helios is detected in bright spots within the liver,
whereas Ikaros is expressed at higher levels throughout the liver.
Helios is expressed in bright spots within the thymus (Th) at E16 (k)
and appears highest in spots near the center of the thymus, while
Ikaros is expressed at high levels throughout the thymus (l). Helios is
also detected in the epithelial linings of the oesophagus (Oe) and
trachea (Tr); CA represents the carotid artery. In addition to expression
in the thymus, Helios can be detected in a number of epithelial tissues
of the day 17 embryo (n), but is no longer detected in the liver at this
stage (lower right). These include epithelial tissue in the lung (Lu),
mouth, salivary glands (S) and ducts (D), tooth bud epithelium
(I represents incisor), olfactory epithelium and skin. Some expression of
Helios in the brain can also be seen.
expression is maintained in the postnatal thymus. Helios is
also detected in a very small subset of cells within the
spleen of the adult (data not shown). 
Outside of the hematopoietic system, Helios expression is
high in a number of epithelial tissues. These include the
endoderm lining the gut, the tubules of the kidney, the
lining of the respiratory tract and the olfactory epithelium.
During late-gestation, high levels of Helios expression can
be detected in the salivary glands and ducts (Figure 2m,n;
T.I. and B.A.M., unpublished observations). In adult
tissues, Helios was detected in the thymus by northern
blot analysis. Although Helios is expressed in the lung,
liver, kidney and brain at various times during embryogen-
esis, it is not detected by northern analysis in these tissues
in the adult (data not shown).
Expression of Helios in hematopoietic subpopulations
The expression of Ikaros gene family members in sorted
hematopoietic and lymphoid progenitors of the adult was
examined by reverse transcription (RT)–PCR. Helios
mRNA is detected in the bone-marrow progenitor popula-
tion that is highly enriched for stem cell activity 
(c-Kit+Sca-1+lineage–) and is also present in hematopoietic
progenitors that have a more restricted lymphoid or
erythromyeloid potential, c-Kit+Sca-1+Sca-2+ and 
c-Kit+Sca-1–Sca-2– respectively [15,16,18,19] (Figure 3a).
Ikaros displays a similar pattern of expression in these
hematopoietic progenitor populations whereas Aiolos is
detected only in the progenitors that are more committed to
lymphoid development, c-Kit+Sca-1+Sca-2+ ([10];
Figure 3a). Helios is not expressed in definitive erythroid
precursors (Ter119+) and very low levels of Helios mRNA
are present within the monocyte (Mac1+GR–) and granulo-
cyte (Mac1+GR+) populations of the adult bone marrow
(Figure 3c). Ikaros is detected at low levels in all three of
these cell types. Helios is present at low levels in pro-B cells
(CD45R+CD43+ from Rag–/– bone marrow) and decreases as
they progress to pre-B cells (CD45R+IgM+). In contrast,
Aiolos expression is low in pro-B cells and dramatically
increases in pre-B and mature B cells. 
As HSCs differentiate along the myeloerythroid and B
lymphoid lineages, Helios expression is diminished. Helios
is present at varying levels in all T cell subsets analyzed,
however (Figure 3b,c). The earliest lymphoid progenitors
entering the thymus are CD4lo (and c-Kit+) and are not
necessarily committed to the T cell lineage [20]. Helios
and Ikaros are both detected in these earliest lymphoid
progenitors. Among the progenitors that are CD4–CD8–,
an increase in Helios expression is apparent during the pro-
gressive transition to the c-Kit+CD25+ and then to the 
c-Kit–CD25+ population [21], in which Aiolos is first
detected (Figure 3b). A marked increase in Aiolos levels is
observed at the next stage of thymocte development 
(c-Kit–CD25–), whereas Helios expression decreases. Ikaros
levels remain constant during these early stages of T cell
differentiation. In Rag–/– mice, all thymocytes are
CD4–CD8– and the majority of these are c-Kit+CD25+
[21,22] due to a block to thymocyte development at this
stage, whereas in a wild-type thymus the majority of cells
are at the double-positive CD4+CD8+ stage of develop-
ment [23] (Figure 3b). Helios mRNA increases as thymo-
cytes progress from the CD4–CD8– double-negative to the
CD4+CD8+ double-positive stage and declines as these
become single-positive (CD4+ or CD8+) thymocytes
(Figure 3c). Peripheral T cells have a lower expression of
Helios than immature thymocytes, with the highest levels
detected in γδ T cells of the skin (Vγ3) and the gut (IEL;
Figure 3c) [25,26]. Ikaros and Aiolos are present in these T
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Figure 3
RT–PCR analysis of Helios expression in hematopoietic cell
populations. Helios, Ikaros and Aiolos expression is shown in sorted
hematopoietic populations using HPRT expression as a control. Th,
thymus; Spl, spleen; DC, dendritic cells; Mon/Mac,
monocyte/macrophage; IEL, intestinal intra-epithelial lymphocytes; NK,
natural killer cells; +/+ Th, wild-type thymocytes. See text for a full
description of the sorted populations.
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B cells T cells
cell populations but Aiolos is not detected in the fetally
derived skin γδ T cells. All three genes are expressed in
NK cells. The lymphoid-derived thymic dendritic cells
(DCs) as well as the splenic CD8+ and CD8– dendritic
subsets express very low levels of Helios. Ikaros is present
in all three populations, but is highest in the splenic CD8–
DC subset. Among the DC subpopulations, Aiolos is also
highest in the splenic CD8– DCs.
Both Helios isoforms (Hel-1 and Hel-2) are expressed at
approximately equivalent levels in all cell types tested.
During hematopoietic development, Helios, Ikaros and
Aiolos have overlapping but distinct patterns of expression.
The differential patterns of expression of these three
factors within the hematopoietic system might underscore
their specific regulatory roles during differentiation.
Helios forms homodimers and heterodimerizes with Ikaros
and Aiolos 
The carboxy-terminal zinc fingers of Ikaros and Aiolos,
which mediate their homodimerization and heterodimer-
ization, are highly conserved in Helios [10,14]. Helios-spe-
cific polyclonal antibodies recognize two Helios isoforms
in thymocyte nuclear extracts from wild-type, Ikaros null
and Ikaros DN+/– mice (Figure 4a). The Helios isoforms
detected in thymocytes are approximately 64 kDa and
68 kDa, and co-migrate with the proteins produced by the
Hel-1 and Hel-2 cDNAs co-expressed after transfection
into the epithelial cell line 293T (Figure 4b, lanes 1,2). 
In cell lysates from the thymuses of mice expressing an
epitope-tagged Ikaros DN isoform, FLAG–Ik-7, both
Helios isoforms were found in complexes immunoprecipi-
tated with a mouse monoclonal antibody to the FLAG
epitope (Figure 4b, lane 3). Thus, Ikaros DN forms a
stable complex with Helios protein isoforms and might
interfere with their normal activity in vivo. Helios also
forms complexes with itself, Aiolos or Ikaros when these
proteins are co-transfected into 293T cells in paired combi-
nations (Figure 4c). Either FLAG–Hel-1 or FLAG–Hel-2
co-precipitate with Ik-1 (Figure 4c, lanes 2,4) and both
Helios isoforms also dimerize with Aiolos (Figure 4c, lanes
6,7). IkM1 contains two point mutations in the carboxy-ter-
minal zinc fingers of Ikaros that disrupt its ability to dimer-
ize [14]. In contrast to Ik-1, this dimerization-deficient
form of Ikaros was unable to interact with either Helios
isoform (Figure 4c, lanes 3,5). Thus, the carboxy-terminal
zinc fingers in Helios, Ikaros and Aiolos are functionally
conserved and mediate the stable interactions between
these proteins which might be critical for hematopoiesis as
well as lymphocyte differentiation and function.
Helios is part of a higher order nuclear structure that
contains Ikaros and Aiolos
Ikaros and Aiolos are part of a higher order structure in
resting lymphocytes that undergoes dramatic changes upon
activation (N.A. and K.G., unpublished observations and
J.H. Wang, et al., unpublished observations). Helios also
participates in these nuclear macromolecular structures in
primary lymphoid cells. In contrast to Ikaros and Aiolos,
bright staining for Helios is detected only in a small
number of either resting or activated thymocytes (approxi-
mately 1 in 25 cells). In resting cells, Helios is detected in a
punctate pattern within the nucleus, similar to that previ-
ously described for Ikaros and Aiolos [10,12,14]
(Figure 5a). Upon thymocyte activation, Helios is redistrib-
uted into ring-like structures in the nucleus (Figure 5c), as
are Ikaros and Aiolos. Helios is also detected in a very
small number of splenocytes. These cells are probably T or
NK cells, as RT–PCR analysis indicated that Helios is not
expressed at significant levels in myeloid, erythroid or
mature B cells.
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Figure 4
Helios homodimerization and heterodimerization with Ikaros and Aiolos.
(a) A polyclonal antibody generated against Helios detects two bands of
approximately 64 kDa and 68 kDa by western blot analysis of thymic
nuclear extracts from wild-type mice (lane 1), Ikaros null mice (lane 2)
and Ikaros DN+/– mice (lane 3). (b) The Hel-1 and Hel-2 isoforms co-
expressed in 293T cells (lane 1), co-migrate with the endogenous
Helios isoforms detected in thymic nuclear extracts (lane 2). Both Helios
isoforms are co-precipitated with Ikaros DN protein from thymuses of
FLAG–Ik-7 transgenic mice (lane 3). (c) Constructs containing genes
encoding Helios, Ikaros or Aiolos were expressed in pairs in 293T cells.
Homodimerization of Helios proteins was demonstrated by precipitation
of the Hel-2–FLAG–Hel-1 complex with the anti-FLAG antibody (lane 1).
Antibodies to Ikaros were used to detect Ik-1 in complexes with either
FLAG–Hel-1 (lane 2) or FLAG–Hel-2 (lane 4) immunoprecipitated using
the FLAG antibody. The dimerization mutant IkM1 was not detected in
immunoprecipitates with either FLAG–Hel-1 (lane 3) or FLAG–Hel-2
(lane 5). FLAG–Aio was expressed with either Hel-1 (lane 6) or Hel-2
(lane 7). Both Helios isoforms were detected in complexes precipitated
with the FLAG antibody. The middle panel confirms the expression of
Hel-1 (lanes 1,2,3,6), or Hel-2 (lanes 1,4,5,7) in the cell lysates. The
lower panel confirms the expression of Ik-1 (lanes 2,4), IkM1 (lanes 3,5),
and Aiolos (lanes 6,7) in the lysates.
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Most cells in the spleen express Aiolos, but only a small
subset of splenocytes also express Helios (Figure 5e–g). In
most cases, there is complete overlap in the expression of
these two proteins in a punctate pattern within the
nucleus. There are a few small spots where either Helios
or Aiolos is detected alone, however. In addition, a few
cells were observed that showed bright staining for Helios,
but only faint staining for Aiolos (data not shown). Cells
stained for Ikaros and Helios showed a similar co-localiza-
tion of the proteins (data not shown). In T cells from the
spleen of mice expressing the FLAG–Ik-7 transgene, the
endogenous Helios and Aiolos proteins co-localize with
Ik-7 in nuclear structures (Figure 5i–l). 
These studies establish the presence of all three family
members in the same structures within the nucleus and
demonstrate that Ikaros DN has the potential to interfere
with the activity of the endogenous Helios and Aiolos pro-
teins by co-localization within the same nuclear com-
plexes. As inferred from the expression profiles of sorted
cells, this immunofluorescence data also confirms the co-
expression of different Ikaros family proteins in varying
combinations within cells of distinct sub-populations in
the thymus and spleen.
Helios can function as transcriptional activator
Helios protein contains a domain that is similar to the tran-
scriptional activation domain of Ikaros and Aiolos. Given
the near identity in the DNA-binding domain between
Helios and Ikaros, we tested the ability of Helios to acti-
vate transcription from Ikaros-binding sites. The expres-
sion of a reporter gene under the control of four
high-affinity Ikaros-binding sites (IkBS2) was tested in
the presence of Helios or Ikaros in NIH3T3 cells [12]. A
fivefold increase in reporter gene expression was detected
in the presence of Helios, and a ninefold increase was
detected in the presence of Ikaros (data not shown).
These results confirm the functional conservation of both
the DNA-binding and transcriptional activation domains
in Ikaros family members. 
Discussion
In the present study, we describe the identification and
characterization of Helios, a new member of the Ikaros
gene family. The proteins encoded by all three genes in
this family have similar properties mediated by conserved
functional domains. All three members bind to the con-
sensus DNA-binding sites characterized for Ikaros and
activate transcription from an adjacent promoter in co-
transfection assays. Like Aiolos and Ikaros, Helios can
dimerize with itself as well as with other family members
including a dominant-negative version of Ikaros. Although
the conservation of these domains emphasizes the similar-
ity of these proteins, other regions differ between the pro-
teins encoded by these genes and might confer functional
specificity among them. The functional significance of
these genes is supported by the fact that the regions that
diverge between family members are conserved in the
orthologs of these genes in other species. Ikaros orthologs
have been reported in the chicken, frog and fish and their
identity is confirmed by our analysis of Aiolos and Helios
orthologs in these species as well ([26,27]; T.I. and
B.A.M., unpublished observations). This analysis has also
revealed that the previously reported partial ‘Ikaros-
related gene’ [17] is the Xenopus homolog of Helios. The
divergent regions include domains that interact with other
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Figure 5
Confocal immunofluorescence demonstrates
co-localization of Helios within nuclear
structures with Ikaros and Aiolos. (a) Bright
staining for Helios (Hel) is detected in nuclear
speckles in some primary resting thymocytes
and (c) in ring structures of activated
thymocytes. (e) Helios is detected only in a
small number of resting splenocytes, whereas
Aiolos (Aio) is expressed in most splenocytes
(f). (g) Double staining shows co-localization
(yellow) of Helios (green) and Aiolos (red) in a
subset of resting splenocytes. (i–k) Staining
for Helios, Aiolos and FLAG–Ik-7,
respectively, in primary splenocytes from mice
expressing the FLAG–Ik-7 minigene from the
T-cell-specific CD2 promoter. (l) Triple
staining shows co-localization of all three
proteins within a subset of cells. (b,d,h,m)
Corresponding bright-field images for the
immunofluorescence studies.
(a) Hel
(e) Hel
(i) Hel (j) Aio (k) FLAG–Ik-7 (l) H+A+F (m)
(f) Aio (g) (h)Hel + Aio
(b) (c) (d)Hel
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proteins which might therefore mediate this functional
specificity (J.K. and K.G., unpublished observations).
The importance of Ikaros and Aiolos in hematopoietic
development has been established by mutational analysis
([6,8,9,28]; J.H. Wang, et al., unpublished observations).
Ikaros and Aiolos are co-expressed at varying levels in
most branches of this lineage and co-localize in macromol-
ecular nuclear complexes ([10]; J.H. Wang, et al., unpub-
lished observations). Recent co-localization studies
suggest that these macromolecular complexes sequester
lineage-specific genes in a repressed state that might be
reversed during lineage progression [29]. Although the
activation of these genes may then require dissolution of
these macromolecular complexes, it is likely that Ikaros
and Aiolos contribute directly to the transcriptional activa-
tion of lineage-specific genes as well, albeit in a different
macromolecular context ([5,30]; A. Nichogiannopoulou
and K.G., unpublished observations). These observations
have led to the model proposing that varying levels of
Ikaros and Aiolos expression in the cell lead to distinct
combinations of heteromeric and homomeric complexes
between these proteins; the functional differences
between these complexes contribute to changes in gene
expression as the lymphoid lineages progress. Consistent
with this model, Aiolos is expressed at higher levels than
Ikaros only in the B cell lineage and defects in Aiolos null
mutant mice are predominantly found in this lineage
([10]; J.H. Wang, et al., unpublished observations). Ikaros
null and DN mutant mice have defects in all lymphoid
lineages that can be attributed to the predominance of
Ikaros expression in lymphoid progenitors and the T cell
lineage. Genetic interactions between different mutant
alleles of Ikaros and Aiolos confirm the data from molecu-
lar analyses showing that these genes co-operate to regu-
late lymphoid development (J.H. Wang et al.,
unpublished observations).
One prediction resulting from analysis of Ikaros DN mice
was that another member of the Ikaros gene family would
co-operate with Ikaros in the earliest stages of the
hematopoietic lineage when Aiolos is not expressed. The
expression of Helios at sites where HSCs arise suggests
that this gene is an important regulator of the earlier
stages of hematopoietic development. Hematopoietic
progenitors accumulate in the yolk sac at embryonic day 8
and the fetal liver at embryonic day 11. Both Ikaros and
Helios are expressed in moderate numbers of cells in
these regions at early stages, although Ikaros expression is
consistently greater than that of Helios. As gestation con-
tinues, these sites are increasingly populated by more
committed erythroid progenitors. Whereas Ikaros expres-
sion increases dramatically in both sites, Helios remains
expressed in a limited number of cells. This may reflect
its preferential expression in the less-committed
hematopoietic progenitors. 
The expression of Helios in sorted hematopoietic cells in
the adult supports this interpretation. Helios is expressed in
adult HSCs but its expression decreases in the maturing
erythroid, macrophage and B cell lineages. Helios expres-
sion peaks in the early stages of T cell development and
decreases as T cells mature in the thymus and are exported
to the periphery. Significant levels of Helios are maintained
in only a small subset of mature T cells. Upon immuniza-
tion, Helios is detected in a very small number of cells in
germinal centers of the spleen that might be T helper cells
(data not shown). When compared with that of Ikaros and
Aiolos, this profile of Helios expression suggests that tran-
scriptional complexes including Ikaros and Helios will pre-
dominate in the earlier stages of hematopoiesis. This
combination may be important for the self-renewing capac-
ity of early progenitors that is compromised in the Ikaros
DN–/– mice (A. Nichogiannopoulou and K.G., unpublished
observations). The increasing expression of Aiolos and
Ikaros as development proceeds may lead to complexes
that promote lineage progression and differentiation.
Whereas Ikaros and Aiolos are predominantly expressed in
hematopoietic sites, Helios is also expressed elsewhere in
the embryo. Although a more detailed analysis of this
expression pattern is required, it is tempting to speculate
that the Ikaros gene family regulates lineage progression
in other tissues as well. The dynamic expression of Helios
in the embryo is consistent with such a role. Mutational
analysis of the Helios gene will help to dissect its role in
regulating progenitor development in the hematopoietic
system and elsewhere in the embryo.
Materials and methods
Cloning of the Helios gene
A 980 bp Helios fragment was obtained from cDNA from the spleen of
an Aiolos–/– mouse (J.H. Wang, et al., unpublished observations) by
PCR using degenerate oligos encoding the GEKPFK and YTIHMG
motifs (single-letter amino-acid code) as previously described [17]. The
RACE–PCR technique (Marathon cDNA Amplification Kit; Clontech)
was used to obtain a full-length clone. PCR analysis of Helios expres-
sion in hematopoietic cells using various combinations of specific 5′
and 3′ primer pairs routinely yielded two bands (corresponding to Hel-
1 and Hel-2). These two bands were cloned and sequenced to show
that the two alternatively spliced transcripts differ in the presence of
sequence encoding the first amino-terminal zinc finger. 
Expression analysis
See supplementary materials for full details of PCR conditions, primers,
and isolation of hematopoietic cell populations. In situ analysis was
carried out essentially as described [31] with single-stranded
[33P]UTP-labeled antisense RNA probes. Slides were exposed for
5 weeks.
Preparation of a Helios-specific polyclonal antibody and
western blot analysis
A Helios peptide from amino acids 223–459 (Figure 1) was generated
using the Xpress system (Invitrogen). Rabbit polyclonal antibodies raised
to this protein were affinity-purified by pH elution [32]. Specificity of this
antibody for Helios and not other Ikaros homologs was confirmed by
western blot analysis of protein extracts from transfected 293T cells (see
below) and by immunofluorescence of transfected cells (data not shown).
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Thymic nuclear extracts were prepared as previously described [14].
Protein lysates were resolved on a 10% SDS–PAGE gel, transferred to
an Immobilon-P membrane (Millipore) and probed with the affinity-purified
polyclonal Helios antibodies (1:500 dilution in PBS/0.05% TWEEN-20).
To detect Helios in primary cells, the signal was amplified by incubation of
the filter with a 1:5 000 dilution of biotinylated goat anti-rabbit antibody
followed by the same dilution of peroxidase-coupled streptavidin (Jackson
Labs). The ECL kit (Amersham) was used for detection.
Expression constructs and transfection of 293T cells 
The full-length Hel-1 or Hel-2 isoforms were cloned into CDM8, creat-
ing CDM8-Hel-1 and CDM8-Hel-2. Additional constructs were gener-
ated containing the FLAG or hemagglutinin (HA) tags (FLAG–Hel-1,
FLAG–Hel-2, HA–Hel-1, HA–Hel-2). Transfections of 293T cells and
immunoprecipitations were performed as described [14]. Western blot
analysis was as described above except that, for 293T extracts, incuba-
tion with affinity-purified polyclonal antibodies specific for Ikaros [12],
Aiolos [10] or Helios was followed by incubation with peroxidase-
coupled goat anti-rabbit secondary antibody. For immunoprecipitation
from primary cells, thymocytes or splenocytes were obtained from trans-
genic mice expressing the FLAG-tagged dominant-negative version of
Ikaros, Ik-7, from the CD2 minigene [33]. Cells were harvested, washed
in PBS/2% FCS, and lysed in 100 µl lysis buffer as described [14]. 
Confocal immunofluorescence
Primary thymocytes or splenocytes were obtained as previously
described [6]. Thymocytes were activated for 40 h as described [8]. Cells
were harvested, cytospun onto slides and fixed in 4% paraformaldehyde. 
Supplementary material
A detailed methodological section is published with this paper on the
internet.
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Materials and methods
Cloning of the Helios gene
PCR using degenerate oligos encoding the sequences GEKPFK and
YTIHMG and cDNA from the spleen of an Aiolos null mouse (J.H.
Wang, N.A., C. Friedrich, T.I., A. Renold, K. Andrikopoulos, L. Liang,
B.A.M., K.G., unpublished observations) was used to obtain a 980 bp
fragment of the Helios gene as described [17]. The RACE–PCR tech-
nique (Marathon cDNA Amplification Kit; Clontech) was used to obtain
a full-length clone using the primers : 5′-RACE R51: GGGTGAAGGC-
CTCAGGT and R52: CCATCATATGAGACTGCATCAGCTCAGC-
CTCC; 3′-RACE R31:
GGAGGCTGAGCTGATGCAGTCTCATATGATGG and R32: CAC-
CTACCTTGGAGCTGAGGCCCTTCACCC (1.5 min, 95°C, 1 cycle;
20 sec, 98°C, 2.5 min, 72°C, 5 cycles; 20 sec, 98°C, 2.5 min, 70°C for
5 cycles; 30 sec, 98°C, 2.5 min, 68°C for 32 cycles; 10 min, 72°C, 1
cycle). A second amplification was 1.5 min, 95°C, 1 cycle; 20 sec,
98°C, 2.5 min, 68°C, 20 cycles; 10 min, 72°C, 1 cycle). PCR analysis
of Helios expression in hematopoietic cells using various combinations
of specific 5′ and 3′ primer pairs routinely yielded two bands. These
two bands were cloned and sequenced. 
RT–PCR analysis of gene expression
RT-PCR conditions and Ikaros and Aiolos primers were as previously
described [10]. HPRT primers (For: TGGCCCTCTGTGTGCTCAAG;
Rev: CACAGGACTAGAACACCTGC) were used as a control for RNA
recovery. Helios primers were: Figure 3b Forward (2F): GGAA-
CACGCCAATATGGCC (nt 60–78 of cDNA) and Reverse (8R):
GGCCTTGGTAGCATCCAAAGC (nt 1327–47). For PCR in Figure
3c, forward primers 1F: AACAGACGCTATTGATGGC (nt 6–24) and
8R were used. The annealing temperature was 60°C and amplification
was determined to be in the linear range. One fifth of the PCR reaction
was loaded on the gel. For bone-marrow-derived progenitor popula-
tions where cells were limiting in number, cDNA from 50 cell equiva-
lents was amplified for 32 cycles. For thymocyte precursors shown in
Figure 3c, amplification was done for approximately 1000 cell equiva-
lents for 26 cycles for each primer pair. All analyses were performed on
at least two (and as many as five) independently sorted populations
with consistent results. The exceptions to this were the IELs in
Figure 3c and the fractionated T cell progenitors in the first four lanes
of Figure 3b where cells from a single sort were analyzed by indepen-
dent PCR reactions.
Isolation of hematopoietic cell populations
Stem cell populations (c-Kit+Sca-1+lineage–), early progenitors (c-
Kit+Sca-1–lineage– and c-Kit+Sca-1+Sca-2+lineage–) were purified
from the bone marrow of wild-type mice as previously described [10].
Lineage-committed erythroid (ter119+), pre B (B220+), granulocyte
(Mac1+GR+), monocyte/macrophage (Mac1+GR–) populations were
purified from bone marrow of wild-type mice using antibodies to cell
surface markers, magnetic secondary antibodies and separated using a
MACS magnetic separation column (Miltenyi Biotec) as previously
described [10]. B220+ pro-B cells were (CD45R+CD43+) sorted from
the bone marrow of Rag–/– mice, B220+ mature B cells were from the
spleens of wild-type mice. Splenocytes from Rag–/– mice were
depleted of red cells and used as an enriched source of NK cells. IEL
αβ and γδ cells were purified according to Lefrancois et al. [S1].
Thymic and splenic dendritic cells were purified as described [28].
Double-positive (CD4+CD8+) and single-positive (CD4+ or CD8+) thy-
mocytes were sorted from wild-type thymus and double-negative
(CD4–CD8–) were obtained from thymocytes of Rag–/– mice that are
arrested at this stage of differentiation. Developmental stages of
double-negative thymocytes (CD4lo, c-Kit+CD25+, c-Kit–CD25+, c-Kit–,
CD25–) were sorted to 98–99% purity as described [20,S2].
Preparation of mammalian expression constructs and
transfection of 293T cells 
The full-length Hel-1 or the Hel-2 isoforms were amplified by PCR from
thymocyte cDNA using primers generated to the 5′ or 3′ ends (5′F:
AATTGAATTCATGCACTGCACTTTGACTATGG and 3′R: TTTTC-
CTTTTGCGGCCGCATGTCGCCATCCGAGGGAAGG) and cloned
into CDM8 creating CDM8-Hel-1 and CDM8-Hel-2. Additional con-
structs were generated containing the FLAG or hemagglutinin (HA)
tags (FLAG–Hel-1, FLAG–Hel-2, HA–Hel-1, HA–Hel-2). 293T cells
were transfected and immunoprecipitations were performed as
described [14]. Western blot analysis was as described above except
that, for 293T extracts, incubation with affinity-purified polyclonal anti-
bodies specific for Ikaros [12], Aiolos [10] or Helios was followed by
incubation with peroxidase-coupled goat anti-rabbit secondary anti-
body. For immunoprecipitation from primary cells, thymocytes or
splenocytes were obtained from transgenic mice expressing the FLAG-
tagged dominant-negative Ikaros isoform Ik-7 from the CD2 minigene
[33]. Cells were harvested and washed in PBS/2% FCS, and 1 × 107
cells were lysed in 100 µl lysis buffer as described [14]. 
Confocal Immunofluorescence
Primary thymocytes or splenocytes were obtained as previously
described [6]. Thymocytes were activated for 40 h on plates precoated
with 20 µg/ml CD3 [8]. Cells were harvested and washed in PBS.
Onto each slide, 1 × 105 cells were cytospun and fixed in 4%
paraformaldehyde, 0.5% TWEEN in PBS at 4°C and then washed in
PBS. Prior to antibody incubation, cells were blocked for 1 h in 3%
BSA, 1% goat serum, 1% donkey serum in PBS. Slides were then
incubated with a 1:50 dilution of primary affinity-purified anti-Helios
antibody in blocking buffer overnight at 4°C, followed by a 60 min incu-
bation at room temperature with a 5 ng/µl biotinylated goat anti-rabbit
IgG (Jackson Labs). Each antibody incubation step was followed by
three washes in PBS. A 45 min incubation with 5 ng/µl avidin–FITC
(Southern Biotechnology Associates) in 1% dialyzed FCS/3% BSA in
PBS was carried out for detection. For double staining, an overnight
4°C incubation with affinity-purified polyclonal anti-Aiolos antibody
directly coupled to the Alexa 568 fluorophore (Molecular Probes) was
performed as the final step. For triple staining of Helios, Aiolos and the
FLAG-tagged Ik-7 in cells from transgenic mice, slides were addition-
ally incubated for 60 min at room temperature with 5 ng/µl anti-FLAG
M5 monoclonal antibody (Kodak), washed and then incubated for
60 min with a 5 ng/µl Cy5-coupled goat anti-mouse antibody (Zymed).
Specific staining was visualized by confocal immunofluorescence
microscopy (Leica). 
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